Summary Slide.png (113.62 kB)
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA): A Multicenter Post-marketing Surveillance Study
media
posted on 2021-01-06, 09:54 authored by Farhad Gharibdoost, Amir-Hossein Salari, Mansour Salesi, Faegheh Ebrahimi Chaharom, Peyman Mottaghi, Mansour Hosseini, Maryam Sahebari, Mohammadali Nazarinia, Zahra Mirfeizi, Mohammadreza Shakibi, Hamidreza Moussavi, Mansour Karimifar, Karim Mowla, Hadi Karimzadeh, Nassim Anjidani, Ahmadreza JamshidiArticle full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
